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Estrogenicity of
Environmental PCBs
The paper by Bergeron, Crews, and
McLachlan, "PCBs as Environmental
Estrogens: Turtle Sex Determination as a
Biomarker of Environmental Contamin-
ation" (EHP 102:780-781) presents data
on the estrogenic activity of 11 chlorinated
biphenyls or diphenyl ethers, or hydroxy-
lated derivatives thereof, selected so as to
represent a variety of structural types.
Some of the PCB types examined (e.g.,
compounds A, C, D, E, and J) arise from
PCB congeners actually detectable in the
commercial Aroclors (1) and hence also in
environmental samples, whereas other
PCB types (e.g., those with heavily uneven
chlorination of the two rings, as in com-
pounds F,G, and L) arise from PCB con-
geners that are not detectable in either the
Aroclors themselves (1) or even environ-
mentally transformed PCB compositions
(2). It is noteworthy that the only com-
pounds found to have statistically signifi-
cant estrogenic activity (compounds F and
G) both represented 4-hydroxylation prod-
ucts of PCB congeners belonging to the
nonenvironmental group, whereas the five
compounds representative of PCB struc-
tures actually present in the environment
were all negative. In short, the results pre-
sent zero evidence that environmental
PCBs present risk ofestrogenic activity.
This is hardly what the authors claim,
however. In their discussion they state (p.
781):
This report contributes laboratory evidence of
the effect ofPCBs on sex determination ... and
serve as a warning of conditions threatening
wildlife populations. The PCB levels reported
here as effective in disrupting normal gonadal
differentiation in the turtles are comparable to
average levels of PCBs found in human breast
milk in industrialized nations.
This most misleading statement repre-
sents a false alarm that can only impede the
search for the environmental contaminants
that actuallydo present estrogenic risk.
Stephen B. Hamilton
Environmental Programs
GE Company
Fairfield, Connecticut
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Response to Hamilton
There are several points we would like to
address in our response. First of all, the
compounds studied were chosen because
these particular congeners were believed to
be estrogenic based on their conformation-
al structure. The primary reason for con-
ducting this type ofstudy was to show the
effectiveness of a temperature-dependent
sex determined (TSD) species as a tool in
assessing estrogenic activity in vivo. This
point is furthered by an earlier report in
EHPby Guillette et al. (1). While the PCB
compounds we used may not be primary
components of commerically available
PCB mixtures, there are parallels between
these compounds and other PCB con-
geners in the pattern ofortho-chlorine sub-
stitutions, as Korach et al. (2) indicate. It is
important to study how these structures
affect a developing organism in order to
understand how PCBs can act as estrogens.
Though these particular congeners may
not be currently used in the readily avail-
able mixtures, McKinney et al. (3) make
reference to goals of using PCBs that are
easily detoxified via hydroxylation. Ifsuch
considerations lead to composition ofcom-
mercially available PCB mixtures away
from congeners that exhibit a dioxinlike
toxicity, these considerations should
include assessment ofthe estrogenic activi-
ty of these compounds. The TSD system
can be used to test such mixtures in vivo.
Furthermore, the appearance of hydroxy-
lated PCB congeners in "nature" is an
emerging issue: for example, Bergman et
al. (4) report that the hydroxylated forms
of heavily chlorinated (penta- or hep-
tachlorinated) biphenyls were among the
most retentive forms of PCBs found in
blood from humans or seals. Clearly, this
class ofmolecules may have environmental
significance which is only now being
appreciated.
The second point that we would like to
emphasize regards the potential for second-
generation exposure to PCBs as environ-
mental estrogens. While the congeners that
we found to clearly exhibit estrogenic
activity may not be produced in the com-
mercial PCB mixtures, or even found in
soil and water samples, they may exist
within animal tissue during metabolism of
the environmental compounds. Maternal
metabolic by-products may affect the
reproductive system at a critical stage in
development of the offspring, producing
the detrimental estrogenic effect on the
second generation. This is particularly a
concern when enhanced estrogenic effects
are produced by the synergy of different
combinations of low-level PCBs, an issue
brought to light by the study in question.
Finally, we share Dr. Hamilton's con-
cern that false alarms may impede identifi-
cation of contaminants that actually pre-
sent risk of estrogenic activity. However,
Dr. Hamilton's cited quotation ofour dis-
cussion, and his interpretation of it,
require clarification so as not to be mis-
leading. Dr. Hamilton's abbreviated quote
would lead readers to believe that it is our
report which we say serves as a warning of
threatening environmental conditions. In
fact, the passage he omitted clearly identi-
fies "the usefulness of a TSD species as a
biomarker" to serve in the capacity which
Dr. Hamilton apparently ascribes to our
report.
Our findings support the call from the
scientific community for the need to fur-
ther study the mechanisms of estrogenic
activity of environmental contaminants.
These findings, together with the growing
body ofevidence that a number ofenviron-
mental compounds mimic estrogens and do
have an effect on developing reproductive
systems, provide ample indication for fur-
ther investigation ofthese mechanisms and
their outcomes. Our report suggests a
model by which to continue these efforts,
and we appreciate the continued interest in
our work and the opportunity to address
questions regarding it.
Judith Bergeron
David Crews
Institute ofReproductive Biology
University ofTexas atAustin
John A. McLachlan
NIEHS
Research Triangle Park, North Carolina
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Human Toxicity of PBDDs and
PBDFs
The brillant literature review and health
risk assessment by Mennear and Cheng-
Chung, "Polybrominated Dibenzo-p-diox-
ins and Dibenzofurans: Literature Review
and Health Assessment" [EHP 102(suppl
1):265-274], states that "reports ofhuman
toxicity associated with exposure to
PBDDs and PBDFs were not found" (p.
272). In fact, in their review, no references
are discussed or quoted regarding human
studies.
Two papers have been published on the
human toxicology ofthese compounds. The
first (1) is a recent report, previously pre-
sented at the Dioxin '90 Congress (2), about
a chemist who was exposed to 2,3,7,8,-
tetrabromodibenzodioxin (TBDD) and to
2,3,7,8-tetrachlorodibenzodioxin (TCDD)
in March and September 1956, respective-
ly, when synthesizing these chemicals. The
chemist was defined as "in good health" in
1990, when determinations of chlorinated
and brominated dioxins and dibenzofurans
were performed on whole blood. High
concentrations of several congeners were
detected, and the results were used to dis-
cuss the half-life of the chemicals in
humans. The subject presented a mild
chloracne after an unspecified time from
his exposure to bromodixoins in March,
suggesting that TBDD could produce skin
effects as chlorodioxins. Other more rele-
vant symptoms occurred after the exposure
to TCDD in September, and the patient
was hospitalized for a short period.
The second was a study of subjects
exposed to PBDDs and PBDFs as a result
of working at a BASF factory in etrusion
blending of polybutyleneterphthalate with
decarbromodiphenyl ether, used as a flame
retardant. The intensity of exposure was
determined in 1989 through air monitor-
ing (3). The paper presents blood levels of
2,3,7,8,-TBDF and TBDD and of total
congener profiles for some exposed work-
ers and the results of a comparison of sev-
eral immunological tests in a population of
exposed versus a population of unexposed
deriving from the same working cohort.
Workers had detectable blood levels of
TBDD and TBDF; half-life estimates of
these chemicals are presented. The results
of immunological tests were described as
"not adversely impacted at these burdens
of PBDFs and PBDDs," even though the
results ofseveral tests showed a correlation
with exposure, and in the subject having
the highest blood levels of PBDFs and
PBDDs, immunological changes were
quite relevant. The authors stated that clin-
ical examination did not reveal "skin
lesions consistent with an acnegenic
response.
It should be stressed that the results of
the two quoted articles do not change the
conclusions of Mennear and Cheng-
Chung on the health risks of PBDDs and
PBDFs. However, slightly different sugges-
tions for future research can be derived.
Human populations have been or are
exposed to these chemicals because oftheir
use in several work processes involving
flame retardants, environmental exposures
(mainly due to municipal incinerators), or
because of accidents due to thermal de-
composition of flame retardants. These
exposed human populations can be suit-
able, at least in theory, for toxicological
and epidemiological observations.
Enzo Merler
Eva Buiatti
Centre for the Study and Prevention of
Cancer
Florence, Italy
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Arsenic Risk Assessment
A commentary highly critical oftwo ofour
published studies was recently published in
EnvironmentalHealth Perspectives (Carlson-
Lynch et al., 102:354-356). One of our
papers examines the epidemiological evi-
dence for a methylation threshold for inor-
ganic arsenic and concludes that there is no
consistent evidence to support the hypoth-
esis ofsuch a threshold in humans (1). The
second paper critiqued by Carlson-Lynch
et al. estimates the human cancer risks of
arsenic at internal sites (lung, liver, kidney,
and bladder) using linear extrapolation
from Taiwanese data (2). Carlson-Lynch et
al. contend that the analyses conducted in
our studies are flawed and that the conclu-
sions reached in our publications are erro-
neous, rendering them unsuitable for use
by the EPA in risk assessment.
Whether or not our studies are used by
the EPA for risk assessment is oflittle con-
cern to us, but we are certainly concerned
about statements that they are flawed.
Careful examination will show that all of
the major points raised in the commentary
are either incorrect or have no valid basis.
We would like to respond to the criticisms
made, point by point, in the order present-
ed, beginning with the methylation paper
(1).
Critique: The average arsenic exposures
in almost all of the studies analyzed were
too low to observe methylation saturation.
Response: The commentators base this
statement on three issues. First, the authors
state that evidence from an experimental
study (ofonly four human volunteers each
receiving only one dose level) suggests that
methylation would be completely saturated
at exposures greater than 500 pg/day (3).
However, at the highest oral dose in this
study, 1000 pg/day, the amount ofurinary
arsenic in the inorganic form was only
26%, hardly demonstrating methylation
saturation even at this level. Buchet et al.
(3) state in their paper that "speciation of
the arsenic metabolites in urine indicated
that the arsenic methylation capacity ofthe
human body was not yet saturated, even
with an oral daily dose of 1000 pg As."
The evidence of any metabolic saturation
from this study is not conclusive. Each of
four arsenic dosing levels was assigned to a
different individual subject, making it
impossible to differentiate interindividual
differences in methylation efficiency from
dose-dependent effects that might apply to
a general population.
Second, the authors state that we ana-
lyzed only two groups with average urinary
arsenic levels at or above 190 pg/I, which
theyhypothesize corresponds to the concen-
tration above which methylation saturation
occurs. This statement obscures the fact that
1) the two groups combined had a total of
35 people, 2) our analysis ofavailable indi-
vidual data (see Figure 2 of our paper)
included 14 persons with urinary arsenic
levels >190 pg/l. No trend ofhigher relative
proportions ofunmethylated arsenic is sug-
gested for those 14 individuals.
Third, the authors state: ". . . a regres-
sion analysis on the individual data within
the Yamauchi et al. [4] population was bor-
derline significant atp = 0.10. . ." (p. 354).
However, this was just one of nine regres-
sion analyses we presented. The slopes were
positive in four (including the Yamauchi
study) but negative in five (1: Table 9).
As a matter of interest, in our more
recent studies ofchronically exposed popu-
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